Vacunas antineumocócicas conjugadas: revisión de la efectividad de las vacunas 10 y 13 valentes frente al neumococo en edad pediátrica

Vaccines pneumococcal conjugate: revision of the effectiveness of vaccines 10 and 13 worthy compared to pneumococcus in age pediatric

  • Valvanuz Martínez Gil Médico Especialista en Medicina Familiar y Comunitaria. Cantabria. España
  • Sara Cabeza Fernández Grado en Enfermería. Hospital Universitario Marqués de Valdecilla. Santander. España
  • Lucía Celis Solar Diplomada en Enfermería. Consejería de Sanidad de Cantabria. España
Palabras clave: Efectividad, Costes, vacunas neumocócicas
Key-words: effectiveness, cost, pneumococcal vaccines

Resumen

Abstract

Bibliografía

1 - European Centre for Disease Prevention and Control. External quality assessment scheme for Streptococcus pneumoniae – 2014. Stockholm: ECDC; 2016. 2 - Nuevas vacunas antineumocócicas conjugadas. Grupo de trabajo de Neumococo. 4 de Febrero de 2010. 3 - Antibody response to pneumococcal vaccination in children younger than five years of age. Douglas RM, Paton JC, Duncan SJ, Hansman DJ. J Infect Dis. 1983;148(1):131). 4 - Ficha técnica de polisacáridos de los serotipos neumocócicos 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F conjugados con proteína transportadora CRM: Prevenar 13®, Pfizer, 18 septiembre 2014. 5 - Domingues CM, Verani JR, Montenegro Renoiner EI, de Cunto Brandileone MC, Flannery B, de Oliveira LH, et al. Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study. Lancet Respir Med 2014;2(6):464-71. 6 - Verani JR, Domingues CM, de Moraes JC; Brazilian Pneumococcal Conjugate Vaccine Effectiveness Study Group. Indirect cohort analysis of 10-valent pneumococcal conjugate vaccine effectiveness against vaccine-type and vaccine-related invasive pneumococcal disease. Vaccine. 2015; 17;33(46):6145-8. 7 - Grando IM, Moraes Cd, Flannery B, Ramalho WM, Horta MA, Pinho DL et al. Impact of 10-valent pneumococcal conjugate vaccine on pneumococcal meningitis in children up to two years of age in Brazil. Cad Saude Publica 2015;31(2):276-84. 8 - Jokinen J, Rinta-Kokko H, Siira L, Palmu AA, Virtanen MJ, Nohynek H, et al. (2015) Impact of Ten-Valent Pneumococcal Conjugate Vaccination on Invasive Pneumococcal Disease in Finnish Children – A Population-Based Study. PLoS ONE 10(3): e0120290. doi:10.1371/ journal.pone.0120290. 9 - Dedeuninck G, De serres G, Boulianne N, Lefebvre B, De Wals P. Efectividad de tres vacunas neumocócicas conjugadas para prevenir la enfermedad neumocócica invasiva en Quebec (Canadá). Vaccine 33(2015) 2684-2689. 10 - Lepoutre A, Varon E, Georges S, Dorléans F, Janoir C, Gutmann L et al. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012. Vaccine 2015; 3;33(2):359-66. 11 - Harboe ZB, Dalby T, Weinberger DM, Benfield T, Molback K, Slotved HC, et al. Impact of 13-Valent Pneumococcal Conjugate Vaccination in Invasive Pneumococcal Disease Incidence and Mortality. CID 2014:59 (15 October). 12 - Chacon-Cruz E, Rivas-Landeros RM, Volker-Soberanes ML. Early trends in invasive pneumococcal disease in children following the introduction of 13-valent pneumococcal conjugate vaccine: results from eight years of active surveillance in a Mexican hospital. Ther Adv Vaccines 2014; Vol.2(6); 155-158. 13 - Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Holtzman C, Harrison LH, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study. Lancet Respir Med 2016;4: 399-406. 14 - Guevara M, Barricarte A, Torroba L, Herranz M, Gil-Setas A, Gil F, Bernaola E, et al. Direct, indirect and total effects of 13-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in children in Navarra, Spain, 2001 to 2014: cohort and case–control study. Euro Surveill. 2016;21(14):pii=30186. DOI: dx.doi. org/10.2807/1560-7917.ES.2016.21.14.30186 15 - Sgambatti S, et al. Early impact of 10-valent pneumococcal conjugate vaccine in childhood pneumonia hospitalizations using primary data from an active population-based surveillance.Vaccine (2015). 16 - Diaz J, Terrazas S, Bierrenbach AL, Toscano CM, Alencar GP, Alvarez A, et al. (2016) Effectiveness of the 10-valent Pneumococcal Conjugate Vaccine (PCV-10) in Children in Chile: A Nested Case-Control Study Using Nationwide Pneumonia Morbidity and Mortality Surveillance Data. PLos ONE 11(4): e0153141. doi:10.1371/journal. pone.0153141. 17 - Gentile A, Bakir J, Bialorus L, Caruso L, Mirra D, Santander C, et al. Impacto de la vacuna neumocócica conjugada 13-valente en la incidencia de neumonía consolidante en menores de 5 años en el partido de Pilar, Buenos Aires: estudio de base poblacional. Arch Argent Pediatr 2015;113(6):502-509. 18 - Gentile A, Juarez MV, Lucion MF, Romanin VS, Giglio N, Bakir J. Influencia de los virus respiratorios en la evaluación de la efectividad de la vacuna neumocócica de 13 serotipos en menores de 5 años: estudio de series temporales 2001-2013. Arch Argent Pediatr 2015;113(4):310-316. 19 - Plosker GL.10-valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D-Conjugate Vaccine; A Review in Infants and Children. Pediatr Drugs (2014); 16:425-444. 20 - Tregnaghi MW, Sáez-Llorens X, López P, et al. Efficacy of Pneumococcal Nontypable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) in Young Latin American Children: A Double-Blind Randomized Controlled Trial. PLoS Med. 2014; 11(6):e1001657. 21 - Sigurdsson S, Kristinsson KG, Erlendsdottir H, et al. An early reduction of acute otitis media and pneumonia in children in Iceland following PCV-10 immunization (abstract). In: European Society for Paedriatic Infectious Diseases, 6-10 May 2014, Dublin. 22 - Sartori AL, Minamisava R, Afonso ET, et al. Reduction in all-cause otitis-related outpatient visits in children after PCV10 introduction in Brazil. Abstract no. ISPPD-0244. In: 9th international symposium on pneumococci and pneumococcal diseases; Hyderabad, India. 2014;3:240. 23 - Ben-Shimol S, et al. Near-Elimination of Otitis Media Caused by 13-Valent Pneumococcal Conjugate Vaccine (PCV) Serotypes in Southern Israel Shortly After Sequential Introduction of 7-Valent/13-Valent PCV. CID 2014:59 (15 December). 24 – Potin M. Vacunas anti-neumocóccicas en población pediátrica: actualización. Rev chilena Infectol 2014; 31 (4): 452-456. 25 – Dagan R, Patterson S, Juergens C, Greenberg D, Givon-Lavi N, Porat N. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial. Clin Infect Dis 2013;57(7):952-62. 26 – Andrade AL, Ternes YM, Vieira MA, Moreira WG, Lamaro-Cardoso J et al. Direct effect of 10-valent conjugate pneumococcal vaccination on pneumococcal carriage in children Brazil. PLoS One. 2014;3;9(6):e98128. 27 – Hammitt LL, Akech DO, Morpeth SC, Karani A, Kihuha N, Nyongesa S, et al. Population effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae in Kilifi, Kenya: findings from cross-sectional carriage studies. Lancet Glob Heatlh 2014; 2:e397-405

Novedades
Estadísticas
Cómo citar
1.
Martínez Gil, Valvanuz; Cabeza Fernández, Sara; Celis Solar, Lucía. Vacunas antineumocócicas conjugadas: revisión de la efectividad de las vacunas 10 y 13 valentes frente al neumococo en edad pediátrica. Nuberos Científica. 13 de julio de 2018; 3(24). Disponible en: http://ciberindex.com/c/nc/2448nc [acceso: 21/09/2018]
Sección
Revisiones bibliográficas
Comentarios

DEJA TU COMENTARIO     VER 0 COMENTARIOS

Normas y uso de comentarios


Hay un total de 0 comentarios


INTRODUCIR NUEVO COMENTARIO

Para enviar un comentario, rellene los campos situados debajo. Recuerde que es obligatorio indicar un nombre y un email para enviar su comentario (el email no sera visible en el comentario).

Nombre:
e-mail:
Comentario: